Cardiovascular disease is the primary cause of morbidity and mortality among the diabetic
population. Both experimental and clinical evidence suggest that diabetic subjects are …

Cyclic guanosine 3', 5'-monophosphate (cGMP) mediates a wide spectrum of physiologic
processes in multiple cell types within the cardiovascular system. Dysfunctional signaling at …

Background—Postnatal growth of the heart chiefly involves nonproliferative cardiomyocyte
enlargement. Cardiac hypertrophy exists in a “physiological” form that is an adaptive …

Cyclic nucleotide phosphodiesterases regulate cAMP-mediated signaling by controlling
intracellular cAMP content. The cAMP-hydrolyzing activity of several families of cyclic …

Heart failure is one of the leading causes of mortality in the western world and encompasses
a wide spectrum of cardiac pathologies. When the heart experiences extended periods of …

Background—Cyclic guanosine monophosphate (cGMP) is the common second messenger
for the cardiovascular effects of nitric oxide (NO) and natriuretic peptides, such as atrial or …

TOPCAT (Treatment of Preserved Cardiac Function Heart Failure with an Aldosterone
Antagonist Trial) trial for efficacy in HF with preserved ejection fraction (HFPEF), a disease …

Increasing evidence suggests that natriuretic peptides (NPs) play diverse roles in mammals,
including renal hemodynamics, neuroendocrine, and cardiovascular functions. Collectively …

This study tested the hypothesis that activation of atrial natriuretic peptide
(ANP)/cGMP/protein kinase G signaling inhibits transforming growth factor (TGF)-β1 …

Objectives: We assessed the hypothesis that in vivo administration of C-type natriuretic
peptide (CNP) might attenuate cardiac remodeling after myocardial infarction (MI) through its …